AAPL   380.18 (-0.31%)
MSFT   212.09 (-0.35%)
FB   240.07 (-1.44%)
GOOGL   1,500.48 (-0.21%)
AMZN   3,087.46 (+0.21%)
NVDA   410.60 (+0.48%)
CGC   15.78 (-3.37%)
BABA   257.08 (-0.23%)
MU   48.95 (-1.53%)
GE   6.63 (-3.35%)
TSLA   1,361.13 (-0.35%)
AMD   54.99 (+2.92%)
T   29.42 (-3.45%)
ACB   11.49 (-5.59%)
GILD   74.60 (-1.34%)
DIS   116.06 (-0.51%)
BAC   22.49 (-2.64%)
NFLX   496.73 (-1.20%)
BA   174.07 (-3.34%)
AAPL   380.18 (-0.31%)
MSFT   212.09 (-0.35%)
FB   240.07 (-1.44%)
GOOGL   1,500.48 (-0.21%)
AMZN   3,087.46 (+0.21%)
NVDA   410.60 (+0.48%)
CGC   15.78 (-3.37%)
BABA   257.08 (-0.23%)
MU   48.95 (-1.53%)
GE   6.63 (-3.35%)
TSLA   1,361.13 (-0.35%)
AMD   54.99 (+2.92%)
T   29.42 (-3.45%)
ACB   11.49 (-5.59%)
GILD   74.60 (-1.34%)
DIS   116.06 (-0.51%)
BAC   22.49 (-2.64%)
NFLX   496.73 (-1.20%)
BA   174.07 (-3.34%)
AAPL   380.18 (-0.31%)
MSFT   212.09 (-0.35%)
FB   240.07 (-1.44%)
GOOGL   1,500.48 (-0.21%)
AMZN   3,087.46 (+0.21%)
NVDA   410.60 (+0.48%)
CGC   15.78 (-3.37%)
BABA   257.08 (-0.23%)
MU   48.95 (-1.53%)
GE   6.63 (-3.35%)
TSLA   1,361.13 (-0.35%)
AMD   54.99 (+2.92%)
T   29.42 (-3.45%)
ACB   11.49 (-5.59%)
GILD   74.60 (-1.34%)
DIS   116.06 (-0.51%)
BAC   22.49 (-2.64%)
NFLX   496.73 (-1.20%)
BA   174.07 (-3.34%)
AAPL   380.18 (-0.31%)
MSFT   212.09 (-0.35%)
FB   240.07 (-1.44%)
GOOGL   1,500.48 (-0.21%)
AMZN   3,087.46 (+0.21%)
NVDA   410.60 (+0.48%)
CGC   15.78 (-3.37%)
BABA   257.08 (-0.23%)
MU   48.95 (-1.53%)
GE   6.63 (-3.35%)
TSLA   1,361.13 (-0.35%)
AMD   54.99 (+2.92%)
T   29.42 (-3.45%)
ACB   11.49 (-5.59%)
GILD   74.60 (-1.34%)
DIS   116.06 (-0.51%)
BAC   22.49 (-2.64%)
NFLX   496.73 (-1.20%)
BA   174.07 (-3.34%)
Log in

NASDAQ:AXSMAxsome Therapeutics Insider Trades

$83.25
-2.59 (-3.02 %)
(As of 07/9/2020 11:05 AM ET)
Add
Compare
Today's Range
$82.87
Now: $83.25
$87.25
50-Day Range
$72.27
MA: $78.71
$85.79
52-Week Range
$13.64
Now: $83.25
$109.94
Volume74,663 shs
Average Volume624,267 shs
Market Capitalization$3.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.13

Insider Trades

Axsome Therapeutics (NASDAQ:AXSM) Insider Buying and Selling Activity

Insider Ownership Percentage: 26.00%

Insider Buying and Selling by Quarter


Axsome Therapeutics (NASDAQ AXSM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/29/2020Mark ColemanDirectorBuy650$78.50$51,025.00  
6/29/2020Nick PizzieCFOBuy777$76.64$59,549.2841,217  
9/26/2019Nick PizzieCFOBuy2,180$24.80$54,064.0040,440  
6/25/2019Mark ColemanDirectorBuy400$23.25$9,300.00653,048  
6/11/2019Nick PizzieCFOBuy1,920$20.80$39,936.001,920  
5/23/2019Mark E SaadDirectorBuy3,500$22.33$78,155.007,002  
5/13/2019Mark ColemanDirectorBuy4,650$21.44$99,696.00652,648  
3/19/2019Mark ColemanDirectorBuy5,100$12.18$62,118.00  
3/19/2019Nick PizzieCFOBuy5,400$12.58$67,932.0036,340  
6/19/2018Nick PizzieCFOBuy31,000$3.10$96,100.00400  
12/23/2015Randall KayeInsiderBuy1,000$9.03$9,030.00  
(Data available from 1/1/2013 forward)
This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.